Sharon R Lewin Selected Research

Inflammation (Inflammations)

1/2017	Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive Antiretroviral Therapy.
1/2016	Immunity in young adult survivors of childhood leukemia is similar to the elderly rather than age-matched controls: Role of cytomegalovirus.
1/2015	Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage.
5/2013	Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses.
8/2012	Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation.
1/2011	Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals.
11/2007	The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sharon R Lewin Research Topics

Disease

46	Infections 02/2022 - 03/2002
34	HIV Infections (HIV Infection) 02/2022 - 10/2002
24	Coinfection 05/2020 - 03/2005
11	Acquired Immunodeficiency Syndrome (AIDS) 10/2021 - 07/2005
10	Neoplasms (Cancer) 02/2022 - 01/2011
10	Latent Infection 01/2021 - 10/2011
8	Hepatitis 06/2021 - 07/2002
8	Cryptococcal Meningitis 01/2019 - 08/2013
7	Viremia 01/2022 - 05/2013
7	Chronic Hepatitis B 06/2021 - 07/2002
7	Liver Diseases (Liver Disease) 01/2017 - 07/2008
7	Inflammation (Inflammations) 01/2017 - 11/2007
7	Fibrosis (Cirrhosis) 01/2016 - 11/2007
6	Immune Reconstitution Inflammatory Syndrome 01/2019 - 07/2008
5	COVID-19 08/2022 - 01/2021
5	Liver Cirrhosis (Hepatic Cirrhosis) 01/2020 - 09/2008
5	Cryptococcosis 01/2019 - 08/2013
5	Hepatitis B 01/2013 - 07/2002
4	Disease Progression 01/2019 - 03/2005
3	Melanoma (Melanoma, Malignant) 01/2021 - 02/2015
3	Cardiovascular Diseases (Cardiovascular Disease) 08/2016 - 03/2011
2	Non-alcoholic Fatty Liver Disease 12/2019 - 01/2019
2	Virus Diseases (Viral Diseases) 01/2018 - 12/2017
1	Lethargy 01/2022
1	Type I Syndactyly 01/2022
1	Ataxia (Dyssynergia) 01/2022
1	Confusion (Bewilderment) 01/2022
1	Merkel Cell Carcinoma 01/2021

Drug/Important Bio-Agent (IBA)

17	RNA (Ribonucleic Acid)IBA 02/2022 - 02/2008
14	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 12/2007
8	Hepatitis B e AntigensIBA 06/2021 - 09/2008
8	Tenofovir (Viread)FDA Link 01/2020 - 04/2009
7	Pharmaceutical PreparationsIBA 01/2022 - 02/2007
6	AntigensIBA 07/2021 - 07/2002
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 03/2002
5	VaccinesIBA 07/2021 - 07/2002
5	Antiviral Agents (Antivirals)IBA 06/2021 - 02/2003
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2011
5	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2020 - 07/2002
5	LipopolysaccharidesIBA 10/2016 - 04/2011
5	ChemokinesIBA 01/2016 - 12/2007
5	Lamivudine (Epivir)FDA Link 01/2016 - 07/2002
4	enhanced green fluorescent proteinIBA 12/2019 - 06/2010
4	Alanine Transaminase (SGPT)IBA 01/2016 - 07/2008
4	Lipopolysaccharide ReceptorsIBA 09/2014 - 03/2011
3	Immune Checkpoint InhibitorsIBA 02/2022 - 01/2018
3	NivolumabIBA 10/2021 - 01/2018
3	IpilimumabIBA 10/2021 - 02/2015
3	CytokinesIBA 06/2021 - 01/2011
3	InterferonsIBA 06/2021 - 01/2013
3	Messenger RNA (mRNA)IBA 01/2021 - 01/2020
3	Interleukin-10 (Interleukin 10)IBA 01/2021 - 05/2013
3	Histone Deacetylase InhibitorsIBA 09/2020 - 01/2011
3	Interleukin-7 (Interleukin 7)IBA 10/2017 - 01/2011
3	Chemokine ReceptorsIBA 01/2016 - 11/2013
2	pembrolizumabIBA 01/2022 - 01/2018
2	Disulfiram (Antabuse)FDA Link 01/2022 - 12/2015
2	Nucleic AcidsIBA 07/2021 - 06/2010
2	LuciferasesIBA 01/2021 - 01/2019
2	Interleukin-6 (Interleukin 6)IBA 01/2021 - 09/2014
2	Vorinostat FDA Link 09/2020 - 07/2013
2	LigandsIBA 01/2019 - 12/2007
2	Emtricitabine (Emtriva)FDA Link 01/2016 - 01/2010
2	EnzymesIBA 09/2014 - 10/2009
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2014 - 11/2007
2	Immunoglobulins (Immunoglobulin)IBA 01/2012 - 07/2002
2	AntibodiesIBA 07/2011 - 10/2009
2	prostratinIBA 04/2011 - 01/2011
2	RacivirIBA 01/2010 - 08/2009
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 08/2022
1	RNA Splice SitesIBA 01/2022
1	Neutralizing AntibodiesIBA 07/2021
1	B-Cell Activating FactorIBA 06/2021
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2021
1	Complement System Proteins (Complement)IBA 01/2021
1	Interleukin-18 (Interleukin 18)IBA 01/2021
1	Signal Recognition ParticleIBA 01/2021
1	avelumabIBA 01/2021
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2021
1	SolutionsIBA 01/2021
1	SofosbuvirIBA 05/2020
1	tat Gene Products (tat Protein)IBA 01/2020
1	Internal Ribosome Entry SitesIBA 01/2020
1	Indicators and Reagents (Reagents)IBA 01/2020
1	tesamorelin FDA Link 12/2019
1	Peptide Elongation Factor 1 (EF-1)IBA 12/2019
1	Small Interfering RNA (siRNA)IBA 01/2019
1	InterleukinsIBA 01/2019
1	Dimethyl Sulfoxide (DMSO)FDA LinkGeneric 01/2019
1	romidepsin (FK228)FDA Link 01/2019

Therapy/Procedure

42	Therapeutics 02/2022 - 03/2005
22	Highly Active Antiretroviral Therapy (HAART) 10/2017 - 02/2007
19	Art Therapy 03/2021 - 10/2009
3	Immunotherapy 01/2021 - 01/2016
3	Aftercare (After-Treatment) 05/2020 - 10/2002
2	Drug Therapy (Chemotherapy) 01/2018 - 01/2016
2	Cesarean Section (Caesarean Section) 01/2012 - 08/2008
1	Stem Cell Transplantation 01/2022
1	Intravenous Administration 01/2022
1	Transplantation 01/2022